Single Colonoscopy Cuts Colorectal Cancer Risk 19% Over 13 Years But Misses Mortality Target
The landmark NordICC trial's 13-year data shows one colonoscopy meaningfully reduces cancer incidence but doesn't significantly lower mortality.
Summary
The NordICC randomized trial followed over 84,000 Europeans for 13 years to assess whether a single colonoscopy screening reduces colorectal cancer incidence and death. Those invited to screening had a 19% lower risk of developing colorectal cancer compared to the unscreened group. Among those who actually completed the colonoscopy, the benefit was even greater — a 45% reduction in incidence. However, colonoscopy screening did not significantly reduce colorectal cancer mortality at 13 years. Notably, cancer death rates in both groups were far lower than originally projected when the trial was designed, suggesting broader improvements in colorectal cancer treatment over time. Benefits were stronger for distal colon cancers and in men compared to women.
Detailed Summary
Colorectal cancer is one of the most common and deadly cancers worldwide, and colonoscopy has long been promoted as the gold standard for early detection and prevention. Yet robust randomized trial evidence for its long-term impact on mortality has been surprisingly limited — until now.
The NordICC trial enrolled 84,583 men and women aged 55–64 from Norway, Poland, and Sweden, randomly assigning them 1:2 to a single invitation for colonoscopy screening or no screening. This latest analysis reports outcomes at 13 years of follow-up, extending earlier 10-year findings.
On the primary outcome of cancer incidence, colonoscopy screening delivered a clear and statistically significant benefit: a 19% reduction in colorectal cancer risk in intention-to-screen analysis (RR 0.81, 95% CI 0.71–0.90), rising to a 45% reduction among those who actually completed screening (per-protocol RR 0.55, 95% CI 0.33–0.81). The benefit was concentrated in distal colorectal cancers (RR 0.79, 95% CI 0.65–0.89; ~21% reduction), while proximal cancer risk was not significantly changed (RR 0.91, 95% CI 0.71–1.09). Men benefited significantly (RR 0.77), while women showed a non-significant trend (RR 0.87, 95% CI 0.70–1.02).
For colorectal cancer mortality, however, the results fell short of statistical significance — RR 0.88 (95% CI 0.68–1.08) in intention-to-screen analysis. Strikingly, observed mortality in the no-screening group was 0.47%, substantially lower than the 0.82% projected at trial design, likely reflecting major advances in colorectal cancer treatment since the trial began.
These findings have important implications. A single colonoscopy does provide meaningful cancer prevention, particularly for the distal colon. The failure to demonstrate a mortality benefit may partly reflect improved treatments making cancer death less likely in both groups, as well as reduced statistical power given lower-than-expected baseline mortality. The trial is registered as ongoing (NCT00883792), with follow-up planned through 15 years, which may yet clarify mortality effects.
Key Findings
- Single colonoscopy reduced colorectal cancer incidence by 19% at 13 years in intention-to-screen analysis.
- Among those who completed screening, incidence dropped by 45% — highlighting the impact of non-compliance.
- Colonoscopy did not significantly reduce colorectal cancer mortality at 13 years (RR 0.88).
- Distal colon cancers were reduced significantly; proximal colon cancers showed no significant benefit.
- Men benefited significantly from screening; women showed only a non-significant trend toward benefit.
Methodology
Multicountry, population-based RCT with 84,583 participants aged 55–64 from Norway, Poland, and Sweden, randomized 1:2 to colonoscopy invitation vs. no screening. Primary outcomes were colorectal cancer incidence and mortality analyzed by intention-to-screen and per-protocol approaches at 13 years of follow-up.
Study Limitations
Summary is based on the abstract only, as the full text is not open access. The intention-to-screen analysis is diluted by low uptake of the colonoscopy invitation, which may understate the true mortality benefit. Observed mortality in both groups was far lower than projected, reducing statistical power to detect a mortality difference.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.